Cost-effectiveness of the influenza vaccine in a healthy, working-age population.
To determine if the influenza vaccine can reduce absenteeism and the cost of Influenza-Like Illness (ILI) in healthy adults in the workplace, a prospective, non-randomized, non-placebo control trial was done in six North Carolina textile plants.
One hundred thirty-one vaccinated employees were compared with 131 age-and gender-matched non-vaccinees from different plants.
Twenty-six (20%) of the vaccinated and 64 (49%) of the unvaccinated group had ILI (P=0.0000008).
Fifteen (11%) of the vaccinated and 31 (24%) of the unvaccinated employees missed work because of ILI (P=0.01).
There were 43 lost workdays in vaccinated and 93 in unvaccinated employees (P=0.00004).
The « cost per saved lost workday » was $22.36, for a company savings of $2.58 per dollar invested in the vaccination program.
We concluded that the influenza vaccine can give significant reductions in incidence, absenteeism, and cost associated with ILI in the workplace.
Mots-clés Pascal : Grippe, Virose, Infection, Vaccination, Programme sanitaire, Prévention, Lieu travail, Impact économique, Absentéisme, Morbidité, Coût, Analyse coût efficacité, Economie santé, Homme, Caroline du Nord, Etats Unis, Amérique du Nord, Amérique
Mots-clés Pascal anglais : Influenza, Viral disease, Infection, Vaccination, Sanitary program, Prevention, Work place, Economic impact, Absenteeism, Morbidity, Costs, Cost efficiency analysis, Health economy, Human, North Carolina, United States, North America, America
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0340235
Code Inist : 002B30A03A. Création : 12/09/1997.